Akebia Therapeutics to Participate in Upcoming Investor Conferences

August 30, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2018-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in the following investor conferences:

- The 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, 2018, at 1:45 p.m. Eastern Time, at the St. Regis New York Hotel.
- The 16th Annual Morgan Stanley Global Healthcare Conference on Friday, September 14, 2018, at 10:30 a.m. Eastern Time, at the Grand Hyatt New York.

A live webcast of the presentations will be available on the company's website at www.akebia.com. To access, please log onto the Akebia website at least 15 minutes prior to the webcasts to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Akebia's website following the conferences.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005583/en/

Source: Akebia Therapeutics, Inc.

Akebia Therapeutics
John Garabo, 617-844-6130
Director, Corporate Communications
jgarabo@akebia.com